Article
A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
AIDS research and human retroviruses - 1 Oct 2012
Kile Deidre A, MaWhinney Samantha, Aquilante Christina L, Rower Joseph E, Castillo-Mancilla Jose R, Anderson Peter L
Abstract excerpt
Atazanavir is a first-line HIV protease inhibitor commonly co-dosed with ritonavir. Ritonavir inhibits atazanavir metabolism, decreasing variability and increasing plasma concentrations. However, ritonavir use results in higher costs and increased drug-related adverse events. Elucidating atazanavir pharmacokinetics might allow for individualized ritonavir boosting. We previously demonstrated that genetically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.